Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia

H. Leblebjian,Kimberly Noonan,Claudia E. Paba-Prada,S. Treon,J. Castillo,I. Ghobrial

DOI: https://doi.org/10.1002/ajh.23985

2015-06-01

Abstract:Age, years Median 63 Range 45–76 Sex, male 9 60% International scoring system for WM Low 1 6 Intermediate 7 47 High 7 47 Baseline IgM prior to CyBorD Median 3,540 Range 1,530–7,700 Baseline M-spike prior to CyBorD Median 2.06 Range 0.07–4.54 Baseline hemoglobin, g/dL Median 8.7 Range 6.7–13.4 Baseline platelet count, 10/L Median 145 Range 30–468 B2-microglobulin >3 mg/dL 14 93 Bone marrow percent involvement* Median 70 Range 40–90 No. of prior therapies No prior therapy 4 27 Prior therapy 11 73 Median number of prior therapy 4 range (1–8) 1–3 4/11 36 4–6 5/11 45 >6 2/11 18 Prior therapy (no. of patients) Rituximab 11 73 Bortezomib 7 47 Alkylators 5 33 Purine nucleoside analogue 4 27 Thalidomide, lenalidomide 2 13 Interferon 1 7 Clinical trial based therapy Panobinostat 4 27 Enzastaurin 2 13 Perifosine 2 13 Everolimus 3 20 No. of patients with concurrent rituximab with CyborD 7 47